Editas Medicine, Inc.

NasdaqGS:EDIT 주식 보고서

시가총액: US$196.5m

Editas Medicine 관리

관리 기준 확인 2/4

Editas Medicine CEO는 Gilmore O’Neill, Jun2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 $ 2.39M, 26.8% 로 구성됩니다. 26.8% 급여 및 73.2% 보너스(회사 주식 및 옵션 포함). 는 $ 258.10K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 258.10K. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 3.9 년입니다.

주요 정보

Gilmore O’Neill

최고 경영자

US$2.4m

총 보상

CEO 급여 비율26.8%
CEO 임기2.4yrs
CEO 소유권0.1%
경영진 평균 재임 기간1.7yrs
이사회 평균 재임 기간3.9yrs

최근 관리 업데이트

Recent updates

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Nov 20
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

CEO 보상 분석

Gilmore O’Neill 의 보수는 Editas Medicine 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

보상 대 시장: Gilmore 의 총 보상 ($USD 2.39M )은 US 시장( $USD 1.46M ).

보상과 수익: Gilmore 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gilmore O’Neill (60 yo)

2.4yrs

테뉴어

US$2,392,309

보상

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

리더십 팀

이름위치테뉴어보상소유권
Gilmore O’Neill
President2.4yrsUS$2.39m0.13%
$ 258.1k
Erick Lucera
CFO & Executive VP1.5yrsUS$2.69m0.028%
$ 55.0k
Linda Burkly
Executive VP & Chief Scientific Officer1.3yrsUS$1.73m0.018%
$ 34.4k
Baisong Mei
Executive VP & Chief Medical Officer2.3yrsUS$1.14m0.052%
$ 101.3k
Feng Zhang
Co-Founder & Scientific Advisory Board Member11.8yrs데이터 없음데이터 없음
George Church
Co-Founder & Scientific Advisory Board Member11.8yrs데이터 없음데이터 없음
Gregory Whitehead
Executive VP and Chief Technical & Quality Officerless than a year데이터 없음데이터 없음
Cristi Barnett
Corporate Communications & Investor Relationsno data데이터 없음데이터 없음
Charlene Stern
Executive VP & General Counselno data데이터 없음데이터 없음
Linea Aspesi
Executive VP & Chief People Officer1.7yrs데이터 없음데이터 없음
Caren Deardorf
Executive VP and Chief Commercial & Strategy Officer1.2yrs데이터 없음데이터 없음

1.7yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: EDIT 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Gilmore O’Neill
Presidentno dataUS$2.39m0.13%
$ 258.1k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno data데이터 없음데이터 없음
George Church
Co-Founder & Scientific Advisory Board Memberno data데이터 없음데이터 없음
Emma Reeve
Independent Chairman of the Board3.2yrsUS$238.24k0%
$ 0
Andrew Hirsch
Independent Director7.5yrsUS$210.56k0.0024%
$ 4.8k
Jessica Hopfield
Independent Director6.8yrsUS$231.07k0.082%
$ 161.1k
Elliott Levy
Independent Director1.6yrsUS$264.88k0%
$ 0
David Scadden
Independent Director5.8yrsUS$213.06k0%
$ 0
Bernadette Connaughton
Independent Director3.1yrsUS$215.06k0%
$ 0
Meeta Chatterjee
Independent Director3.9yrsUS$205.56k0%
$ 0

3.9yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: EDIT 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.